Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Nov 30;12(11):2979-2983.
doi: 10.21037/tcr-23-1431. Epub 2023 Oct 26.

HER destiny too

Gerald M Higa  1
Affiliations
Editorial

HER destiny too

Gerald M Higa. Transl Cancer Res. .
No abstract available

Keywords: Destiny; trastuzumab deruxtecan (T-DXd); trastuzumab emtansine (T-DM1).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The author has completed the ICMJE uniform disclosure form (available at https://tcr.amegroups.com/article/view/10.21037/tcr-23-1431/coif). The author has no conflicts of interest to declare.

Comment on

References

    1. André F, Hee Park Y, Kim SB, et al. Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial. Lancet 2023;401:1773-85. 10.1016/S0140-6736(23)00725-0 - DOI - PubMed
    1. Doi T, Shitara K, Naito Y, et al. Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study. Lancet Oncol 2017;18:1512-22. 10.1016/S1470-2045(17)30604-6 - DOI - PubMed
    1. Tamura K, Tsurutani J, Takahashi S, et al. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study. Lancet Oncol 2019;20:816-26. 10.1016/S1470-2045(19)30097-X - DOI - PubMed
    1. Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012;367:1783-91. 10.1056/NEJMoa1209124 - DOI - PMC - PubMed
    1. Krop IE, Kim SB, González-Martín A, et al. Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol 2014;15:689-99. 10.1016/S1470-2045(14)70178-0 - DOI - PubMed